Nanox Stock: Why This Saga Is Best Avoided

August 12. 2023. 7 mins read

“We’re going to wait until regulatory approval happens and revenues start trickling in before we take another look at Nanox (NNOX).” That’s what we wrote nearly three years ago in a piece titled Nanox Reinvents X-Ray Machine, Files IPO which noted the company’s goal – “to finalize deployment of the initial 15,000 Nanox Systems by 2024.” Our response was to quote the great American philosopher Mike Tyson – “everyone has a plan until they get punched in the mouth.”

Three Years Later

Three years later and the plan to have 15,000 x-ray machines in the field has moved to three years following an FDA approval that took place in spring of this year.

Screenshot of  headline article showing "Nanox scores clearance for cloud-connected x-ray bed after years of FDA review"
It’s finally here – whatever “it” is – Credit: Fierce Biotech

Following receipt of clearance from the FDA, and if authorized by similar regulatory agencies in other jurisdictions, our goal is to finalize deployment of the initial 15,000 Nanox System units within three years following receipt of FDA clearance for our multi-source Nanox.ARC (including the Nanox.CLOUD).

Credit: Nanox

Why three years? Wasn’t the $100 million from the

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.